| Price | $0.82 |
| Year Range | $0.68 – $2.45 |
| Market Cap | $42M |
| Industry | Biotechnology |
What Is Filana Therapeutics’s AI Stock Analysis?
Filana Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Filana Therapeutics’s momentum in near-real time.
Filana Therapeutics (FLNA) has an AltIndex AI Score of 55/100, currently a Hold signal. The AI Score distills Filana Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Filana Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Filana Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving FLNA’s AI Score?
Fundamentals
Revenue for the last quarter was $0. This is equal to the revenue of the quarter before it, showing stability. Also, this is equal to the revenue of the same quarter last year, indicating consistency. Net income for the last quarter was $-8.6M. This is an increase of -16.73% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -80.55%, suggesting positive year-over-year growth. Ebitda for the last quarter was $-9.1M. This is an increase of -9.86% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -79.34%, suggesting positive year-over-year growth.
See Filana Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $0.82. This is an increase of 2.50% compared to a month ago, indicating a positive short-term trend. However, compared to a year ago, there is a decrease of 80.43%, which could be a cause for long-term concern. The trend is bullish. The current SMA10 is $0.90, which is higher than the previous SMA10 of $0.89. This indicates a potential upward trend in price movement. The RSI is 44.9, indicating a neutral condition.
See the full technical analysis and price prediction.
Sentiment & social
The sentiment for the stock on various stock forums is high, a positive sign.
Track Filana Therapeutics’s market sentiment.
Frequently Asked Questions: Filana Therapeutics AI Stock Analysis
Filana Therapeutics's AltIndex AI Score is 55/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Filana Therapeutics a Hold (55/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Filana Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the FLNA AI Score or sign up to read the full thesis.
